Age-Related Maculopathy Statin Study

INTERVENTION: Two tablets of simvastatin, 20 mg each, daily. The planned duration of the intervention/control is five years. CONDITION: Age‐related macular degeneration PRIMARY OUTCOME: Progression of high risk early AMD to late AMD. SECONDARY OUTCOME: Dynamics of Visual Functions: Colour sensitivity, Flicker sensitivity, Bleach recovery, Kinetics of Dark adaptation. INCLUSION CRITERIA: (1) The ability to assess the macula in at least one eye, (2) VA better than or equal to 6/18 in the study eye(s). (3) High risk drusen in both eyes: one or more large soft druse (125 microns), or >10 intermediate drusen (62.5 microns) ORLate AMD (CNV, GA) in one eye and any drusen or pigment change in the study eye.Note: the study eye is allowed to have non‐central GA and/or non‐neovascular PED (4) cholesterol level within the normal limits according to the person's medical history (5) not currently on any cholesterol‐lowering medication.